Holen Sie sich die Stockscreener-App
0.6399
5.61%
0.034
Handel nachbörslich:
.63
-0.0099
-1.55%
Athira Pharma Inc Aktie (ATHA) Neueste Nachrichten
Errors Lower Fee Award For Athira Pharma Investors' Counsel - Law360
US Penny Stocks: November 2024's Top Picks To Consider - Simply Wall St
Perceptive Advisors LLC Acquires Significant Stake in Athira Pha - GuruFocus.com
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal - MSN
Athira Pharma to Present Results from Phase 2/3 LIFT-AD - GlobeNewswire
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting - StockTitan
Athira Pharma faces Nasdaq delisting over share price - Investing.com
A closer look at Athira Pharma Inc (ATHA)’s stock price trends - US Post News
A year in review: Athira Pharma Inc (ATHA)’s performance in the last year - US Post News
A Guide To The Risks Of Investing In Athira Pharma Inc (ATHA) - Knox Daily
Analytical Overview: Athira Pharma Inc (ATHA)’s Ratios Tell a Financial Story - The Dwinnex
Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by Forefront Analytics LLC - Defense World
Wall Street SWOT: Athira Pharma stock faces crossroads after Alzheimer's trial setback - Investing.com
Athira Pharma Inc (ATHA) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Athira Pharma stock plunges to 52-week low of $0.41 - Investing.com
Athira Pharma stock plunges to 52-week low of $0.41 By Investing.com - Investing.com Canada
Taking a look at what insiders are doing to gauge the Athira Pharma Inc (ATHA)’s direction - Knox Daily
Check out these key findings about Athira Pharma Inc (ATHA) - SETE News
Was Athira Pharma Inc (ATHA)’s session last reading good? - US Post News
Athira Pharma to lay off 70% of workforce - PharmaLive
Athira Pharma Inc (ATHA) Becoming More Attractive for Investors - Knox Daily
Market Watch Highlights: Athira Pharma Inc (ATHA) Ends on an Downturn Note at 0.43 - The Dwinnex
Athira Pharma to Lay Off 70% of Workforce - BioSpace
After Alzheimer's stumble, Athira lays off 70% of workforce and pivots to ALS small molecule - Fierce Biotech
Athira Pharma stock faces pivot and workforce cuts amid trial setbackMizuho - Investing.com Canada
Athira Pharma Inc [ATHA] Officer makes an insider purchase of 5,032 shares worth 1.0. - Knox Daily
Athira Pharma stock hits 52-week low at $0.46 amid market challenges - Investing.com
Athira Pharma downgraded to Neutral from Outperform at Mizuho - TipRanks
Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Down 8.7% in August - Defense World
Taking the lead: Athira Pharma Inc (ATHA) - SETE News
Athira Pharma Inc Inc. (ATHA) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Athira Pharma Inc (NASDAQ: ATHA): Slumped -75.09% In 2024, Outlook Stable - Stocks Register
Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter
Athira Pharma lays off 70% of its staff as company shifts focus - The Business Journals
Athira Pharma to Cut About 70% of Workforce - MarketWatch
Athira Pharma to focus on ATH-1105 advancement, reduces workforce by 70% - TipRanks
Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring - GeekWire
Athira’s Alzheimer’s Drug Fails in Later-stage Clinical Trial - Being Patient
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - GlobeNewswire
Market Recap Check: Athira Pharma Inc (ATHA)’s Negative Finish at 0.51, Up/Down -4.18 - The Dwinnex
Is Athira Pharma Inc (ATHA) a opportunity to investors? - US Post News
Athira Pharma Inc [ATHA] Investment Guide: What You Need to Know - Knox Daily
Market Update: Athira Pharma Inc (ATHA) Sees Positive Movement, Closing at 0.51 - The Dwinnex
AdPha urges HTA reform - Pharmacy Daily
Fosgonimeton fails to meet goal in Alzheimer’s clinical trial: Data - Alzheimer's News Today
Athira Pharma stock plunges to 52-week low of $0.46 By Investing.com - Investing.com Australia
Ready to Jump After Recent Trade: Athira Pharma Inc (ATHA) - SETE News
Athira Pharma stock plunges to 52-week low of $0.46 - Investing.com
Rodman & Renshaw downgrades Athira Pharma Inc (ATHA) rating to a Neutral - Knox Daily
ATHA’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Recent Insider Activity Suggests Potential Gains for Athira Pharma Inc (ATHA) - Knox Daily
Closing Bell Recap: Athira Pharma Inc (ATHA) Ends at 0.54, Reflecting a -3.65 Downturn - The Dwinnex
StockWatch: Athira Pays Price as Alzheimer’s Candidate Fails Trial - Genetic Engineering & Biotechnology News
Athira Pharma executive sells shares on clinical trial milestone By Investing.com - Investing.com Australia
Athira Pharma (ATHA) Stock Price, News & Analysis - MarketBeat
Athira Pharma COO Rachel Lenington sells shares worth $1,429 - Investing.com India
Athira plunges as Alzheimer’s trial setback leads to downgrades - MSN
Athira Pharma CEO sells over $2.8k in company stock - Investing.com
Athira Pharma COO Rachel Lenington sells shares worth $1,429 By Investing.com - Investing.com Canada
Athira Pharma executive sells shares worth $1,429 By Investing.com - Investing.com UK
Athira Pharma tanks as fosgonimeton misses in Alzheimer’s trial | Pharmaceutical | The Pharmaletter - The Pharma Letter
Athira Pharma (NASDAQ:ATHA) Downgraded by BTIG Research to Neutral - Defense World
Athira Pharma (NASDAQ:ATHA) Downgraded to Neutral at Rodman & Renshaw - Defense World
5.11%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):